Stay updated on Pembrolizumab for Lung Cancer Prevention Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Lung Cancer Prevention Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Lung Cancer Prevention Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The value 'Participation Criteria Collaborators - No information provided' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change indicates a shift in focus towards the specific criteria researchers are seeking in participants for the clinical study.
    Difference
    50%
    Check dated 2024-05-22T08:22:29.000Z thumbnail image
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 'Recruiting Contact: Daniel Sterman 212-731-6162 Daniel.Sterman@nyulangone.org Principal Investigator: Daniel Sterman 08 10' to 'Active, not recruiting Laura and Isaac Perlmutter Cancer Center at NYU Langone Texas Locations Houston, Texas, United States, 77030 Recruiting M D Anderson Cancer Center Contact: Jianjun Zhang 713-792-6363 JZhang20@mdanderson.org Principal Investigator: Jianjun Zhang'. This change indicates a shift in the recruitment status and contact information for the study, possibly reflecting updates in the medical and healthcare-related activities.
    Difference
    0.6%
    Check dated 2024-05-21T08:01:30.000Z thumbnail image
  6. Check
    12 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change represents an update in the estimated primary completion date and study completion date for the clinical trial involving pembrolizumab in preventing lung cancer in patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules.
    Difference
    0.0%
    Check dated 2024-05-14T02:23:09.000Z thumbnail image
  7. Check
    15 days ago
    Change Detected
    Summary
    The value 03 2024 2024 01 03 has recently changed to 10 2025 2025 08 (Estimated) 10. This change represents an update in the estimated study completion date from January 2024 to July 2025, indicating a potential extension in the timeline for the clinical trial related to preventing lung cancer using pembrolizumab.
    Difference
    0.3%
    Check dated 2024-05-11T19:27:35.000Z thumbnail image
  8. Check
    20 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change represents an update in the estimated primary completion date and study completion date for the clinical trial investigating the use of pembrolizumab in preventing lung cancer in patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules.
    Difference
    0.0%
    Check dated 2024-05-06T18:51:59.000Z thumbnail image
  9. Check
    22 days ago
    Change Detected
    Summary
    The value 02 22 02 21 02 22 02 on the webpage has recently changed to 05 03 05 01 (Estimated) 05 03 05. This change likely represents an update or new information related to the study on pembrolizumab for preventing lung cancer in patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules.
    Difference
    0.5%
    Check dated 2024-05-04T09:59:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Lung Cancer Prevention Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Lung Cancer Prevention Clinical Trial page.